Recent clinical trials demonstrate the efficacy and quality-of-life benefits of radiation therapies in cancer treatment. A decade-long study found stereotactic radiation matches surgery for early-stage non-small cell lung cancer survival. The NRG-GU005 Phase III trial revealed stereotactic body radiation therapy (SBRT) preserves bowel health better than standard intensity-modulated radiation in intermediate-risk prostate cancer patients. The TORPEdO trial indicated proton beam therapy and IMRT offer comparable outcomes in oropharyngeal cancer. Additionally, combined radiopharmaceutical and SBRT approach significantly extended progression-free survival in oligometastatic prostate cancer.